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Abstract
Background: Although multimorbidity has important implications for patient care in general
practice, limited research has examined chronic illness and health service utilisation among problem
drug users. This study aimed to determine chronic illness prevalence and health service utilisation
among problem drug users attending primary care for methadone treatment, to compare these
rates with matched 'controls' and to develop and pilot test a valid study instrument.
Methods: A cross-sectional study of patients attending three large urban general practices in
Dublin, Ireland for methadone treatment was conducted, and this sample was compared with a
control group matched by practice, age, gender and General Medical Services (GMS) status.
Results: Data were collected on 114 patients. Fifty-seven patients were on methadone treatment,
of whom 52(91%) had at least one chronic illness (other then substance use) and 39(68%) were
prescribed at least one regular medication. Frequent utilisation of primary care services and
secondary care services in the previous six months was observed among patients on methadone
treatment and controls, although the former had significantly higher chronic illness prevalence and
primary care contact rates. The study instrument facilitated data collection that was feasible and
with minimal inter-observer variation.
Conclusion: Multimorbidity is common among problem drug users attending general practice for
methadone treatment. Primary care may therefore have an important role in primary and
secondary prevention of chronic illnesses among this population. This study offers a feasible study
instrument for further work on this issue. (238 words)
Background
Injecting drug users have an increased mortality compared
to the general population. Mortality rates of 13–30 per
thousand persons per year (an age-adjusted mortality rate
of 6.9–22.0) have been reported among injecting drug
users, with opiate overdose and HIV infection the major
causes of death [1-5].
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The introduction of 'harm reduction' interventions (ie
interventions designed to prevent problems associated
with problem drug use, eg oral methadone treatment,
needle and injecting paraphernalia exchange pro-
grammes) has, in addition to advances in HIV treatment,
been an important factor in reducing mortality/increasing
life expectancy among problem drug users [6-8]. One
might therefore expect an 'epidemiological shift', as
chronic illnesses and their complications replace infec-
tious diseases and drug overdose as causes of death. In this
respect, an association between problem drug use and
subsequent decrease in general self-rated health has been
demonstrated [9].
While bloodborne virus infections (in particular hepatitis
C [10-12]), psychiatric illness [13] and to a lesser extent,
problem alcohol use [14] are all recognised as chronic
medical problems that are more prevalent among inject-
ing drug users, our understanding of other 'common'
chronic illnesses among injecting drug users is less
advanced. While much is known about the epidemiology
and management of diabetes, cardiovascular disease and
chronic respiratory illness (eg asthma, COPD) and while
the prevention and management of these chronic illnesses
has been identified as a priority issue for population
health in Ireland and globally [15,16], no data have
reported on the epidemiology or care of these illnesses
among current or former drug users.
The aims of this study were:
- to determine chronic illness/multimorbidity preva-
lence and health service utilisation among problem
drug users attending primary care for methadone treat-
ment and to compare these rates with matched 'con-
trols';
- to develop and pilot test a valid study instrument.
Methods
Setting
The study was carried out in Dublin city, where an esti-
mated 16.0 per thousand of the population currently use
illicit opiates [17]. In Ireland, addiction treatment is cur-
rently provided by specialist addiction treatment services,
including a central Drug Treatment Centre Board, regional
addiction centres, community-based projects (satellite
clinics) and by primary care. Most recent data reported
that 7845 patients were treated for problem drug use by
these agencies in 2002, with opiates the most common
drug for which people attended for treatment (86% of
total) [18].
In recent years, the number of general practitioners (GPs)
prescribing methadone has increased in Ireland, the UK
and elsewhere in the EU [19-23]. To prescribe methadone
in Ireland, GPs must complete special training and are
subject to clinical audit, with GPs who provide metha-
done treatment for 15 or more patients subject to more
regular audit and advanced training ('level 2' GPs) [24].
This system is analogous to the 'GPs with a special inter-
est' ('GPWsi') model currently operating in the UK [25].
Initiation of methadone treatment is only permitted in
specialist addiction clinics or by 'level 2' GPs [24]. In all
other cases, chaotic opiate users are initially cared for in a
specialist addiction clinic and their care then transferred
to general practice when stable. In circumstances where
illicit drug use of patients attending general practice
becomes 'chaotic', addiction care is transferred to the spe-
cialist addiction services.
The study was conducted in three large group general
practices (see Table 1), all situated in areas of high depri-
vation and with practice populations predominantly eligi-
ble for General Medical Services (GMS) scheme (the
scheme that at the time of the study provided free primary
care services to approximately 30% of the Irish population
on the basis of age over 70 years or low income). Each
practice used both electronic and hard copy clinical
records, but at the time of the study, each had been using
electronic records alone for all new clinical and prescrib-
ing notes for at least six-months. Each practice was
research-active and formally affiliated with one of Dub-
lin's three medical schools.
Subjects
All patients attending each practice for methadone treat-
ment on 1st July 2008 were eligible for the study. A consid-
Table 1: Characteristics of practices that participated in study.
Practice Description Approximate number of patients on methadone 
treatment at practice
Clinical records
A 3.0 FTE doctor teaching general practice in Dublin's 
south inner city
19 Combined electronic/paper
B Four doctor teaching general practice in Dublin's 
south inner city
45 Combined electronic/paper
C 2.5 FTE general practice in Dublin's north inner city 70 Combined electronic/paperBMC Family Practice 2009, 10:25 http://www.biomedcentral.com/1471-2296/10/25
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erable variability in numbers of patients attending the
three practices for methadone existed at the time of the
study, with 19 the smallest number of patients attending
one of the practices for methadone treatment and hence
19 cases were sampled at each practice.
Sampling of 'cases'
At each participating practice, the researcher and GP iden-
tified cases for inclusion in the study by random number
sampling from a numbered list of patients attending that
practice for methadone treatment (in Ireland, GPs are not
allowed to issue a prescription for methadone for any
more than two weeks and are remunerated on a 'per con-
sultation' basis).
Sampling of 'controls'
Controls were matched for practice, age, GMS scheme
membership and gender. Potential controls were identi-
fied by running a query of 'active patients' registered on
each practice's electronic practice management informa-
tion system using the matching criteria. This list of poten-
tial controls was then numbered and one control
identified using random number sampling.
Data collection and validation
Data was collected from clinical records. A study instru-
ment was developed for the purpose of this study (see
Appendix 1). The instrument was based on another
instrument routinely used to collect health information
on current or former injecting drug users in Ireland, the
Health Research Board National Drug Treatment Report-
ing System (NDTRS) [26]. Data were therefore collected
on:
￿ Demography
￿ Addiction care
￿ Chronic illnesses
￿ Presentations with acute illnesses
￿ Prescribing
￿ Health service utilisation (including: attendance at
primary care, secondary care, out of hours services,
emergency departments and diagnostic investiga-
tions).
Data were collected by four researchers over the course of
two weeks in July 2008: one researcher (SOB) collected
data on all records and at each practice, one of the GPs at
that practice (WC, FDOK or AOC) also collected data.
Data was extracted from the 'diagnosis' 'prescribing', 'con-
sultation', and 'communication' modules from individual
electronic clinical records. In addition, paper records were
reviewed for: 'active diagnoses/chronic illnesses', and hos-
pital referral/update/discharge letters.
At consecutive intervals, the researchers compared the
data collected to determine the degree of inter-observer
variability; this check was conducted after six, 12, 19, 38
and 57 records of patients on methadone had been
reviewed. At each review, questions with an inter-observer
agreement of less than 90% and questions where data
extraction had proved problematic were revised and these
revisions were incorporated into subsequent iterations of
the study instrument. A log of the data collection process
was maintained, with the amount of data collected in one
three-hour sessional block and problems in data collec-
tion recorded.
Data analysis
Data were analysed using Statistical Packages for the
Social Sciences (SPSS) version 12.0. Analytical techniques
included Pearson's chi squared test to determine the sig-
nificance of associations between categorical variables.
Odds ratios and their 95% confidence intervals (CI) were
used to compare rates of chronic and acute illness and
health service utilisation between the two groups (cases
and controls).
Ethical considerations
All data were collected and/or reviewed by a GP with clin-
ical responsibility for the patient's ongoing care. The strat-
egy whereby GPs were involved in data collection was
adopted for two reasons: to optimise data accuracy and in
case any health issue was identified that may require a
subsequent clinical intervention. Any subsequent clinical
interventions were not included in the data collection.
The Irish College of General Practitioners Research Ethics
Committee approved this study. We did not seek patient
consent for review of clinical records by the researcher/
their GP. However, ethical safeguards included the follow-
ing:
- all data were collected anonymously and any details
that could potentially identify individuals were
removed after data collection;
- all members of the research team were nominated as
'agents' of each practice and each signed a confidenti-
ality agreement with the other participating practices.
Results
Feasibility and validity of data collection
Data were collected on a sample of 114 patients attending
three general practices: 57 'cases' attending for methadone
treatment (19 per practice) and 57 'controls' (19 per prac-BMC Family Practice 2009, 10:25 http://www.biomedcentral.com/1471-2296/10/25
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tice) matched by practice, age, gender and GMS status.
While considerable inter-observer variation was apparent
at the initial stages of data collection, this variation dimin-
ished as the study instrument was subsequently modified
(See Table 2). For the final seven cases at Practice A, the
two researchers disagreed on the answers to 2/36 ques-
tions. In addition, later versions of the study instrument
facilitated a more efficient data collection process that
allowed one researcher to collect data on 19 patients in
three three-hour 'sessions' in the case of Practice B and
two three-hour 'sessions' in the case of Practice C.
Demographic and addiction characteristics of patients on 
methadone treatment
The mean age of 'cases' was 37.2 years (standard devia-
tion: 7.25 years), 42(74%) were male, 41(72%) had GMS
cover, all were Irish nationals and 56(98%) were docu-
mented as living in stable accommodation.
Considerable lifetime contact with the practice was
observed: 16 patients (28%) had been attending the prac-
tice for less than 5 years, 21 patients (37%) for 5–10 years
and 20 patients (35%) for in excess of 10 years. Treatment
of illicit drug use (20 patients), registration for general
medical care (20 patients) and being referred by specialist
addiction treatment services for methadone treatment (17
patients) were the reasons why patients had first attended
(see Table 3). All patients that had been referred for meth-
adone treatment by the specialist addiction treatment
services had been with the practice for 10 years or less.
Considerable contact with specialist addiction services
(both lifetime and since commencing methadone treat-
ment at the practice) was also observed among the sam-
ple. All patients had been prescribed methadone by
specialist addiction services prior to attending the general
practice for methadone treatment and 14(25%) patients
had been referred back to specialist addiction services for
methadone treatment since commencing methadone
treatment at the practice (six in the previous year).
The mean daily dose of methadone prescribed (on the last
issued prescription) was 66 milligrammes (standard devi-
ation: 26 milligrammes). Tobacco/cigarette smoking sta-
tus was recorded in the records of 39 patients (68% of
total), of whom 37 were recorded as smokers.
Morbidity among patients on methadone treatment
Fifty-two patients (91%) had a chronic illness (in addi-
tion to substance/opiate/drug use) documented in their
clinical record (mean chronic illnesses per patient: 2.6,
standard deviation: 1.7). Table 4 indicates the number of
patients with pre-determined chronic illnesses that were
sought during the data collection and in the case of each,
the number who had attended secondary care for that
problem. Hepatitis C, depression, asthma and HIV/AIDS
were the most common illnesses (38, 20, 14 and 8
patients respectively). A wide range of chronic illnesses
that had not been pre-determined were also recorded
among patients on methadone treatment. Of these 47
chronic illnesses, back pain (5 patients), gastritis/chronic
dyspepsia/gastro-oesophageal reflux (4 patients) and
DVT/varicose veins/thrombophlebitis (four patients)
were the most common. Thirty-nine patients (68% of
total) were on regular prescribed medication, in addition
to methadone, (mean medications per patient: 2.4, stand-
ard deviation: 3.0).
Thirty-one patients (54%) had an acute illness during the
previous three-months, (mean acute illnesses per patient:
1.0, standard deviation: 1.5). Upper respiratory tract
infection (10 patients), sleep disturbance/anxiety/feeling
depressed (four), abdominal pain (four), urinary tract
infection (three) and ear wax (three) were the most com-
monly documented acute illnesses.
Twenty-five patients (44% of total) had been prescribed at
least one time-limited medication (in addition to metha-
done) for the treatment of an acute illness during the pre-
vious three months (mean medications per patient: 0.9,
standard deviation: 1.5).
Table 2: Description of data collection process from clinical records of patients being prescribed methadone.
Practice Clinical records Items with inter-observer 
disagreement/total
Workload (in number of three-hour sessions) involved in data collection to 
collect data
Lead researcher GP researcher
2.0 1.0
7–12 7/34 1.5 1.0
13–19 2/36 1.0 0.5
B 20–38 0/39 3.0 0.5
C 39–57 0/39 2.0 0.3BMC Family Practice 2009, 10:25 http://www.biomedcentral.com/1471-2296/10/25
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Health service utilisation among patients on methadone 
treatment
In the previous six months, patients on methadone had
attended their GP for issues other than their addiction
care a mean of 3.9 times (standard deviation: 4.1), and
had attended another healthcare professional in the prac-
tice a mean of 0.5 times (standard deviation: 0.8). Three
patients had used the out of hours services provided by
the practice and ten patients (18%) had at least one diag-
nostic investigation arranged or performed by the prac-
tice. A total of 23 such investigations were performed on
these ten patients, which included: biochemistry/haema-
tology (13), microbiology (six), cervical smears (three)
and radiology (one).
In the previous six months, 27 patients (47%) had either
been referred to, or attended secondary care, with Emer-
gency Department (10 referrals/attendances), infectious
diseases (10 referrals/attendances), gastroenterology (8
referrals/attendances), hepatology (6 referrals/attend-
ances), addiction services (4 referrals/attendances) and
psychiatry (3 referrals/attendances) the secondary care
services to which patients were most commonly referred/
attended.
Comparison with 'control' group
The mean age of 'controls' was 37.2 years (standard devi-
ation: 0.44), 42(74%) were male, 41(72%) had GMS
cover and all were Irish nationals. Thirty-eight (67%) were
documented as living in stable accommodation.
Among the 'control' group (n = 57), morbidity and health
service utilisation rates were also high, with 40(70%) hav-
ing a documented chronic illness and 23(40%) being pre-
scribed recurrent medications. In the previous six months,
27(47%) had consulted with a healthcare professional at
the practice, 19(33%) were referred to secondary care and
11(19%) had investigations performed by the practice. In
the previous three months, 21(37%) had attended with
an acute illness.
Table 4 highlights a lower prevalence of psychological ill-
ness, bloodborne virus infection and respiratory illness
among 'controls'. Table 5 compares morbidity and health
service utilisation characteristics of patients on metha-
done with controls. Patients attending for methadone
treatment were significantly more likely to have a chronic
illness, to be prescribed recurrent medications and to con-
sult with a GP or other healthcare professional at the prac-
Table 3: Reasons why, and time since, patients on methadone first attended practice.
Reason first attended practice First attended the practice <10 years ago First attended the practice >10 years ago Total
Treatment of illicit drug use 11 9 20
Referred by addiction services for methadone 
treatment
17 0 17
General medical care 9 11 20
Total 37 20 57
Table 4: Prevalence of, and attendance at secondary care for specific chronic illnesses same.
Chronic illness (ICPC code) Number of patients with illness documented/number who have attended secondary care for this 
illness (cases)
'Cases' 'Controls'
Diabetes-Insulin Dependent (T90) 1/1 0/0
Diabetes – Non Insulin Dependent (T91) 1/1 1/0
Heart valve disease (K83) 1/1 0/0
Asthma (R96) 14/1 6/1
Chronic obstructive pulmonary disease (R95) 2/1 0/0
Depression (P76) 20/14 6/2
Viral hepatitis (D72): hepatitis C 38/24 1/0
Viral hepatitis (D72): hepatitis B 6/4 2/1
HIV/AIDS (B90) 8/8 1/1
Anxiety Disorder (P74) 2/1 1/1
Chronic alcohol abuse (P15) 5/0 0/0
Other chronic illnesses documented 47/27 52/27BMC Family Practice 2009, 10:25 http://www.biomedcentral.com/1471-2296/10/25
Page 6 of 10
(page number not for citation purposes)
tice. Although they were also more likely to have attended
with and be prescribed medication for acute illnesses and
to have been referred to secondary care, these differences
were not statistically significant.
Discussion
Key findings
The proportions of cases (patients on methadone) and
controls that had a chronic illness, that were prescribed
regular medication, that attended with acute illnesses and
that consulted with primary/secondary care were high,
although patients on methadone treatment were more
likely to have at least one chronic illness recorded, to be
prescribed regular medications and to have attended pri-
mary care.
Methodological considerations
Validity of the data reported in this paper is likely to have
been enhanced by the practices in which it was conducted
(research-active, with advanced practice information sys-
tems) and the method of data collection (two researchers
validating and cross-checking data that had been extracted
and a study instrument developed to minimise variation
between researchers).
However, we acknowledge a number of potential sources
of bias. Participating practices had a longstanding clinical
and research interest in problem drug use. While not rep-
resentative of practices providing methadone treatment in
Dublin, we considered them an appropriate environment
for exploratory research on this subject.
Ascertainment bias is also possible as patients on metha-
done must attend their GP every 1–2 weeks in Ireland
[24]. As data were collected from clinical records, it is pos-
sible that frequent attendance (for methadone treatment)
may increase documentation of chronic illnesses. It is also
possible that this review of clinical records may have
under/over reported other behaviours such as smoking.
Selection bias was also possible, as patients with less
severe and extreme problem drug use do not attend gen-
eral practice for methadone treatment in Ireland.
Such considerations notwithstanding, the sample was
comparable to larger samples of patients attending gen-
eral practice for methadone treatment in Ireland in terms
of gender and bloodborne virus status, but was older
[27,28].
How this relates to other literature
Work conducted in a similar setting to ours has identified
a number of barriers to multimorbidity research and these
include: problems with practice software, variations in
disease coding and accurately determining primary and
secondary care activity through clinical records [29].
While our experience would support these barriers and
while morbidity data extracted from clinical records will
inevitably be determined by clinical record keeping, we
suggest that adopting a study instrument that is already
being used in primary care [26] and modifying this to
minimise inter-observer variation, can yield consistent
data across practices.
Our findings regarding multimorbidity and chronic ill-
ness among patients on methadone treatment are consist-
ent with North American studies that have reported
higher prevalence of medical and psychiatric conditions
among problem substance users [30,31]. Our findings
Table 5: Patients attending for methadone treatment compared to randomly sampled population matched by practice, age, gender 
and GMS cover.
Patients on methadone Randomly sampled control 
population
Odds ratio 
(95% confidence interval)
Chi squared (p value)
Chronic illness 52/57 40/57 4.4(1.5–13.0) 8.11(< 0.005)
On recurrent medications 39/57 23/57 3.2(1.5–6.9) 9.05(< 0.005)
Attendance with acute illness a 31/57 21/57 2.0(1.0–4.3) 3.54(0.06)
Medication prescribed for acute 
illness a
25/57 15/57 2.2(1.0–4.8) 3.85(0.05)
Attended GP/healthcare 
professional at practiceb
45/57 27/57 4.2(1.8–9.5) 12.2(< 0.001)
Referred to/attended secondary 
care b
27/57 19/57 1.8(0.8–3.8) 2.33(0.13)
Attended practices' out of hours/
deputising service b
3/57 5/57 0.6(0.1–2.5) 0.54(0.46)
Has had investigations performed/
arranged by practice b
10/57 11/57 0.9(0.3–2.3) 0.06(0.81)
a in previous 3 months; b in the previous 6 months.BMC Family Practice 2009, 10:25 http://www.biomedcentral.com/1471-2296/10/25
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regarding health service utilisation is consistent with other
work which show illicit drug users more likely to use
Emergency Department and primary care [32].
While chronic respiratory disease may not yet be widely
recognised as such, this study highlights the potential
importance of its prevention and treatment among prob-
lem drug users. We anticipated the prevalence of other
chronic illnesses (eg chronic alcohol abuse, diabetes,
hypertension, ischemic heart disease) might have been
higher and reasons for this and incidence rates should be
explored in further research, especially as the cohort ages.
In time, it is possible that adverse lifestyle factors will
increase the incidence of these chronic illnesses, thereby
leading to more complex care.
This study has also documented a high prevalence of
chronic illness, incidence of acute illness and high contact
rates with primary/secondary care among 'controls', find-
ings which may be explained by the study being con-
ducted in areas of high deprivation [33].
Implications for research and clinical practice
This pilot study has highlighted a need for further research
on the epidemiology of chronic illnesses among patients
on methadone. A larger, more representative sample of
practices would make for more generalisable findings
regarding illness prevalence. Conducting such research at
practices from a range of socio-economic areas would
allow controlling for deprivation as a potential con-
founder. Longitudinal studies would enable determina-
tion of incidence of key chronic illnesses, with data being
collected directly from patients as well as from clinical
records.
Such research should explore opportunities for primary
and secondary prevention of chronic illness and deter-
mine uptake of primary care interventions in chronic ill-
ness management.
In this pilot study, a 21% difference in chronic illness
prevalence rates between 'cases' and 'controls' was docu-
mented. However, chronic illness prevalence rates among
problem drug users and 'controls' may have been higher
in our study for reasons discussed above. Allowing for a
more conservative estimate of chronic illness prevalence
among (general) young adult populations of 48% [34], a
21% difference among problem drug users, we estimate
data on 86 patients on methadone and 86 controls would
determine a statistically significant difference in chronic
illness prevalence rates (assuming significance of 0.05,
power of 0.90 and a case:control ratio of 1:1).
If the findings of this pilot study are supported by more
powerful/representative studies, then screening and treat-
ment of chronic illness and increasing care complexity
will be important issues in the future management of
problem drug users. Therefore, an integrated care model,
in which primary care and addiction care both care for
problem drug users may best address this population's
health needs [35].
Conclusion
Multimorbidity is common among problem drug users
attending general practice for methadone treatment, and
primary care may have an important role in primary and
secondary prevention of chronic illnesses among this
group. Further work on chronic illness and health service
utilisation among problem drug users is advocated and
this study offers a feasible study instrument.
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Appendix 1. Final draft of study instrument
A. Administrative details
HSE area of practice
East Coast
Northern
South western
Southern
NW
Midland
Western
Mid western
NE
Type of addiction treatment
Being prescribed methadone at present: Yes No
Primary agency managing addiction problem:
GP Addiction clinicBMC Family Practice 2009, 10:25 http://www.biomedcentral.com/1471-2296/10/25
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Client number ____________(Note deleted from final
electronic file)
B. Demography
Gender Male Female
Age last birthday
DOB
Health cover GMS Non-GMS
GMS number (Note deleted from final electronic file)
Living where
Stable accommodation
Institution
Homeless
Other
Not Known
Area of residence
DED ______________
CCA ______________
County registration plate ______________
ationality
Irish
Irish traveller
Other
Not known
C. D. E. Addiction care details
Date first referred to/attended general
practice _____________
Main reason for first referral/attendance (tick)
Alcohol use
Illicit drug use
Licit drug use
Referred by specialist addiction services for metha-
done treatment
General medical care/GMS registration
Other
Was the patient prescribed methadone by any other
agency/clinic before attending the practice for methadone
treatment:
Yes No
What is the earliest recorded date on which the patient
was prescribed methadone by any agency/clinic (01/
month/year) _____________
What is the earliest recorded date on which the patient
was prescribed methadone at this practice (01/month/
year) _____________
Has the patient attended any other agency/clinic for
addiction treatment since the above date (21b)?
Yes No
Has the patient attended any other agency/clinic for
addiction treatment in the last 12 months?
Yes No
Date last treatment episode with methadone commenced
_____________
Dose of methadone at last prescription
_________MILLIGRAMMES PER DAY
F. Chronic disease
Which illnesses that require ongoing follow up have been
documented at the time of data being collected and/or at
any time in the past and in the case of each has patient
attended secondary care for this problem
- Diabetes-Insulin Dependent (T90)
- Diabetes – Non Insulin Dependent (T91)
- Cardiac arrhythmia (K80)
- Rheumatic fever (K71)
- Ischaemic heart disease with angina (K74)
- Acute myocardial infarction (K75)BMC Family Practice 2009, 10:25 http://www.biomedcentral.com/1471-2296/10/25
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- Ischaemic heart disease (K76)
- Heart failure (K77)
- Pulmonary heart disease (K82)
- Heart valve disease (K83)
- Heart disease other (K84)
- Hypertension complicated (K87)
- Asthma (R96)
- Chronic obstructive pulmonary disease (R95)
- Depression (P76)
- Viral hepatitis (D72): hepatitis C
- Viral hepatitis (D72): hepatitis B
- HIV/AIDS (B90)
- Anxiety Disorder (P74)
- Chronic alcohol abuse (P15)
- Other chronic illnesses
Documented acute illnesses in the preceding 3 months
(and their ICPC-2 code)
If the patient attended today for a repeat prescription,
what medication would be prescribed? Medication
(generic name)/route
Acute/non-recurrent medications in the last 3 months:
medication (generic name)/route
In the last 6 months, number of consultations (excluding
those concerning ONLY methadone) with:
- a doctor in the practice: ____________
- another healthcare professional in the
practice: ____________
Has patient been referred to or attended secondary care
(including emergency departments) in the last 6 months?
Yes No
If yes, please specify: specialty/date referred by practice/
date attended specialty
Has patient attended out of hours/GP deputising service
in the last 6 months?
Yes No
If yes, please specify: Date/Problem/ICPC code
Has patient had a diagnostic investigation arranged/per-
formed by the practice in the last 6 months (excluding
urine toxicology)? Yes No
If yes, please specify: pathology/diagnostic imaging/other
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